NARRATOR: As you know, people with HAE don't have enough working C1 inhibitor protein. This causes another protein, kallikrein, to become overactive. This increase in kallikrein activity results in the release of too much bradykinin, the substance that causes HAE attacks. Today, there's TAKHZYRO®, a plasma-free treatment that decreases kallikrein activity.
NARRATOR: It's a first-of-its-kind subcutaneous injection taken once every two weeks to help prevent HAE attacks in people 12 years of age and older. TAKHZYRO is a type of treatment known as a therapeutic antibody. These medications, which are actually proteins, have been used to treat a variety of conditions and work by targeting specific substances in the body.
NARRATOR: In the case of TAKHZYRO, the target is kallikrein. Think of kallikrein as a faucet that controls the flow of bradykinin. In HAE, the faucet is turned all the way up, causing attacks. The key ingredient in TAKHZYRO, lanadelumab, decreases kallikrein activity to turn down the faucet. This slows the release of bradykinin, bringing levels closer to normal to prevent HAE attacks.
NARRATOR: TAKHZYRO (lanadelumab) is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 12 years of age and older. It is not known if TAKHZYRO is safe and effective in children under 12 years of age. TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms: wheezing, difficulty breathing, chest tightness, fast heartbeat, faintness, rash, and/or hives.
NARRATOR: The most common side effects seen with TAKHZYRO were injection site reactions (pain, redness and bruising), upper respiratory infection, and headache. These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist. You may report side effects to the FDA at 1-800-FDA-1088. TAKHZYRO has not been studied in pregnant or breastfeeding women. Talk to your healthcare provider about the risk of taking TAKHZYRO if you are pregnant, plan to be pregnant, are breastfeeding, or plan to breastfeed.
NARRATOR: Talk to your healthcare provider about TAKHZYRO, the only preventive HAE treatment you take as a subcutaneous injection just once every two weeks.